NCT05566093

EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors

Endoscopic Ultrasound-guided Fine-needle Injection for Nonfunctional Pancreatic Neuroendocrine Tumors: a Prospective Multicenter Study

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Guangxi Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The current study aims to access the feasibility, safety, and efficacy of EUS-FNI for nonfunctional pNETs

Detailed description

The management of nonfunctional pancreatic neuroendocrine tumors (NF-pNETs) remains controversial. In general, surgical resection is the standard treatment for NF-pNETs. However, the incidence of postoperative adverse events of surgical resection is relatively high. Recently, several studies have revealed that endoscopic ultrasonography (EUS)-guided fine-needle injection (EUS-FNI) with ethanol or lauromacrogol may offer an effective treatment for pNETs. Therefore, a multicenter prospective study is being conducted to further identify the efficacy and safety of EUS-FNI for NF-pNETs.

Conditions

• Nonfunctional Pancreatic Neuroendocrine Tumor
• Pancreatic Neuroendocrine Tumor
• Endoscopic Ultrasound

Interventions

Type	Name	Description
PROCEDURE	EUS-guided ethanol ablation	After puncturing with the needle, 95% ethanol under the guidance of EUS was injected into the tumor. The injection volume of ethanol was estimated according to the following principles: (1) The injection volume was not larger than the tumor spherical volume. (2) Injection volume was reduced when the tumor was adjacent to the pancreatic duct or vessel. (3) Injection volume for the lesions with repeated EUS-FNI was reduced.
PROCEDURE	EUS-guided lauromacrogol ablation	After puncturing with the needle, lauromacrogol under the guidance of EUS was injected into the tumor. The injection volume of lauromacrogol was estimated according to the following principles: (1) The injection volume was not larger than the tumor spherical volume. (2) Injection volume was reduced when the tumor was adjacent to the pancreatic duct or vessel. (3) Injection volume for the lesions with repeated EUS-FNI was reduced.

Timeline

• Start date: 2018-09-28
• Primary completion: 2025-12-31
• Completion: 2025-12-31
• First posted: 2022-10-04
• Last updated: 2022-10-04

Locations

1 site across 1 country: China